Legal psilocybin therapy in Czechia (2026): who qualifies and when it starts
The short answer. Since 1 January 2026, Czech law allows psilocybin as a medical treatment for defined forms of depression. Only a psychiatrist, or a doctor with a specialisation in medical psychotherapy, can prescribe and give it, and only after registered medicines have failed or were not tolerated (Government Regulation 552/2025).
It has not started yet. On 23 March 2026, the National Institute of Mental Health (NUDZ) said it was "not yet possible to apply for psilocybin treatment or to register for a waiting list". It expected the launch in the second half of 2026, once reimbursement from public health insurance is finalised (NUDZ). As of 23 October 2026 we found no public announcement that treatment had begun.
What the law says
Act No. 270/2025 Coll. amended Czech drug and medicines law, with effect from 1 January 2026. The detailed rules are in Government Regulation No. 552/2025 Coll., published on 17 December 2025, which also took effect on 1 January 2026. Psilocybin must also be used in line with the clinical guideline on psilocybin-assisted psychotherapy (Czech Psychiatric Society).
This is a national medical route, not an EU approval. No psilocybin medicine is authorised by the EU or under EMA evaluation: see our EMA approval tracker and the Czechia tracker row.
Who qualifies
Under the regulation, psilocybin can be used only where registered medicines were ineffective or caused documented intolerance, and only for (Regulation 552/2025, §2):
- depressive disorder associated with cancer;
- clinically serious depressive disorder without psychotic symptoms;
- a sudden worsening of another serious neuropsychiatric or mental disorder that seriously threatens the patient's life, where this is sufficiently supported by scientific evidence.
A psychiatrist decides whether a patient is suitable. One prospective provider, Psyon, says treatment will at first be only for treatment-resistant depression, and that expressing interest "does not mean automatic inclusion" (Psyon).
How treatment works under the rules
- Who gives it: a doctor specialised in psychiatry, or with a special specialisation in medical psychotherapy. It is an individually prepared medicine (made up for the patient, not a mass-produced authorised product), given by mouth only and prescribed on a special controlled-drug requisition (§2).
- Where: in specialised healthcare facilities (NUDZ).
- Dose limits: no more than 35 mg and 0.4 mg per kg in a single dose; no more than 75 mg and three doses per calendar month, at least seven days apart. If three doses in a row bring no clinically significant improvement, psilocybin must not be used again (§3).
- Supervision: the doctor who gives the dose supervises the patient for at least 4 hours for doses up to 14.99 mg, and at least 6 hours from 15 mg. Supervision ends only when the doctor confirms the effects have fully worn off (§4).
When it starts
NUDZ says the law formally allows psilocybin treatment in specialised healthcare facilities, but that availability depends on finalising reimbursement under public health insurance. In March 2026 it expected the launch in the second half of 2026 (NUDZ, English; Czech). Psyon also says treatment is likely in the second half of 2026 (Psyon). We will update this page when treatment opens.
Who has said they will provide it
Our directory lists the National Institute of Mental Health (NUDZ), based in Klecany near Prague, and Psyon in Prague, a prospective provider. Listing is for information only and is not a recommendation. All Czechia listings.
Psilocybin trials with sites in Czechia
Generated from the Psyche Insights directory. When we checked ClinicalTrials.gov on 23 October 2026, the palliative-care study listed its NUDZ site as recruiting, while the CYB003 study listed its three Czech sites as not yet recruiting (NCT06782724; NCT06793397).
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Condition
- Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder
- Sponsor
- Cybin IRL Limited
- Phase
- Phase 3
- Czech sites
- Two sites in Prague and one in Předměstí, all listed as not yet recruiting (checked 23 October 2026)
- Countries
- Australia, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, United States
- Overall status
- Recruiting (ClinicalTrials.gov)
- Registry record
- ClinicalTrials.gov NCT06793397
- Last checked
- 23 October 2026
Psilocybin Therapy for Psychological Distress in Palliative Patients
- Condition
- COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis)
- Sponsor
- University Medical Center Groningen
- Phase
- Phase 2
- Czech sites
- National Institute of Mental Health (listed as Prague), recruiting (checked 23 October 2026)
- Countries
- Czechia, Denmark, Netherlands, Portugal
- Overall status
- Recruiting (ClinicalTrials.gov)
- Registry record
- ClinicalTrials.gov NCT06782724
- Last checked
- 21 October 2026
Questions and answers
Is psilocybin therapy legal in the Czech Republic?
Yes, as a medical treatment, since 1 January 2026. Psilocybin can only be prescribed and given by a doctor specialised in psychiatry (or with a special specialisation in medical psychotherapy), for defined depressive disorders, after registered medicines have not worked or were not tolerated.
Who qualifies for psilocybin treatment in Czechia?
The regulation lists three situations: depressive disorder linked to cancer; clinically serious depressive disorder without psychotic symptoms; and a sudden worsening of another serious neuropsychiatric or mental disorder that seriously threatens the patient's life, where scientific evidence sufficiently supports it. In each case registered medicines must have been ineffective or not tolerated.
When does psilocybin treatment start in Czechia?
The law has been in force since 1 January 2026, but treatment depends on reimbursement from public health insurance being finalised. On 23 March 2026, NUDZ said patients could not yet apply or join a waiting list, and expected the launch in the second half of 2026. As of 23 October 2026 we found no public announcement that treatment had started.
Can I sign up for psilocybin therapy in Czechia now?
According to NUDZ, not yet: it said in March 2026 that it was not yet possible to apply for treatment or register for a waiting list. Decisions will be made by the treating psychiatrists under the clinical guideline.
How much psilocybin is allowed per dose?
The regulation caps a single dose at 35 mg and 0.4 mg per kg of body weight, with no more than 75 mg and three doses in a calendar month, at least seven days apart. The doctor must supervise the patient for at least 4 hours (doses under 15 mg) or 6 hours (15 mg and above), until the effects have fully worn off.
Does this make magic mushrooms legal in Czechia?
No. This framework covers psilocybin prescribed by a psychiatrist and taken under medical supervision in healthcare. It does not allow non-medical use, and this guide covers only the medical route.
Česky: krátké otázky a odpovědi
Je léčba psilocybinem v Česku legální?
Ano, od 1. ledna 2026 jako lékařská léčba. Individuálně připravovaný léčivý přípravek s psilocybinem smí předepsat a podat pouze lékař se specializovanou způsobilostí v oboru psychiatrie nebo se zvláštní specializovanou způsobilostí v oboru lékařská psychoterapie, a to při neúčinnosti nebo zdokumentované nesnášenlivosti léčby registrovanými léčivými přípravky (nařízení vlády č. 552/2025 Sb.).
Kdy bude léčba psilocybinem dostupná?
NUDZ v březnu 2026 uvedl, že se k léčbě zatím nelze přihlásit ani zapsat na čekací listinu a že zahájení očekává ve druhé polovině roku 2026. Dostupnost závisí na dokončení úhrady z veřejného zdravotního pojištění.
Zdroje: nařízení vlády č. 552/2025 Sb.; NUDZ, oficiální prohlášení.
Get UK and Europe access news each week
New trials, regulator decisions and law changes, with every claim linked to its source. Free, one email a week.
Subscribe free →Sources
Hand-written facts and links checked 23 October 2026. Trial records checked on the dates shown.
- Government Regulation No. 552/2025 Coll. on psilocybin for medical use (Czech, e-Sbírka). https://www.e-sbirka.cz/sb/2025/552
- Act No. 270/2025 Coll. (Czech, e-Sbírka). https://www.e-sbirka.cz/sb/2025/270
- National Institute of Mental Health (NUDZ): official statement on the availability of psilocybin treatment (23 March 2026). https://www.nudz.cz/en/news-and-events/official-statement-on-the-availability-of-psilocybin-treatment
- NUDZ: Oficiální prohlášení k dostupnosti léčby psilocybinem (Czech). https://www.nudz.cz/aktuality-a-akce/oficialni-prohlaseni-k-dostupnosti-lecby-psilocybinem
- Czech Psychiatric Society: clinical guideline on psilocybin treatment (Czech). https://postupy-pece.ceskapsychiatrie.cz/lecba/lecba-psilocybinem
- Psyon: therapeutic psilocybin information page (Czech). https://www.psyon.cz/lecebny-psilocybin/
- ClinicalTrials.gov NCT06782724 (psilocybin in palliative care), site list. https://clinicaltrials.gov/study/NCT06782724
- ClinicalTrials.gov NCT06793397 (CYB003 / HLP003), site list. https://clinicaltrials.gov/study/NCT06793397